ANIX Earnings & Financial Statements
Anixa Biosciences, Inc.
$2.88
-$0.04(-1.20%)
34
Overall
40
Value
36
Tech
28
Quality
Market Cap
$101.16M
Volume
152.25K
52W Range
$2.32 - $5.46
Target Price
$9.67
ANIX earnings and financial statements: Anixa Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ANIX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $210.0K | $210.0K | - | $512.0K |
| Cost of revenue | - | - | $161.0K | $13.88M | $385.0K |
| Operating income | -$11.70M | -$13.83M | -$11.01M | -$13.88M | -$13.14M |
| EBITDA | -$12.37M | -$12.66M | -$748.88M | -$13.83M | -$13.08M |
| Net income | -$10.93M | -$12.55M | -$9.81M | -$13.60M | -$12.95M |
| EPS (diluted) | $-0.34 | $-0.39 | $-0.32 | $-0.45 | $-0.45 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $16.08M | $21.59M | $25.52M | $30.41M | $36.26M |
| Total liabilities | $2.13M | $2.70M | $2.15M | $2.21M | $1.49M |
| Shareholders’ equity | $15.16M | $20.00M | $24.34M | $29.05M | $35.44M |
| Cash and equivalents | $1.24M | $1.27M | $915.0K | $12.36M | $29.13M |
| Long-term debt | $163.0K | $203.0K | $123.0K | $175.0K | $220.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.17M | -$7.33M | -$6.21M | -$6.49M | -$4.94M |
| Capital expenditure | - | - | - | - | $35.0K |
| Free cash flow | -$7.17M | -$7.33M | -$6.21M | -$6.49M | -$4.94M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANIX | $2.88 | -1.2% | 152.25K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |